NCT03942497|Completed
Loading search results
Sponsor study identifier
observational
218
1 country
9
Study Start
August 1, 2019
Actual (reported)Primary Completion
August 31, 2021
Actual (reported)Study Completion
February 28, 2022
Actual (reported)The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 28, 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 25, 2019
Actual (reported)May 8, 2019
Actual (reported)August 1, 2019
Actual (reported)August 31, 2021
Actual (reported)February 28, 2022
Actual (reported)Epidemiology
Overall survival (OS) will be defined from the date of treatment initiation to date of death from any cause. In case of patients that received palliative care only, OS will be defined from date of diagnosis of advanced disease to date of death from any cause. Patients who are alive will be censored at the date of last known contact.
2 years
Socioeconomic chactacteristcs
2 years
Overall response
2 years
Duration of response
2 years
PFS
2 years
Patients with recurrent/ metastatic urothelial carcinoma diagnosed between January 2016 to July 2018.
CLION
Salvador, Estado de Bahia, Brazil
Clínica AMO
Salvador, Estado de Bahia, Brazil
Hospital São Rafael
Salvador, Estado de Bahia, Brazil
LIGA
Curitiba, Paraná, Brazil
CPO Pucrs
Porto Alegre, Rio Grande do Sul, Brazil
CEPON
Florianópolis, Santa Catarina, Brazil
Beneficência Portuguesa
São Paulo, São Paulo, Brazil
1. Milowsky MI, Rumble RB, Booth CM, et al. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016;34(16):1945-1952. doi:10.1200/JCO.2015.65.9797 2. Instituto Nacional de Câncer José Alencar Gomes. Estimativa 2018: Incidência de Câncer No Brasil. Rio de Janeiro: INCA; 2018. http://www.inca.gov.br/estimativa/2018. 3. International Agency for Research on Cancer, International Association of Cancer Registries. Cancer Incidence in Five Continents. Volume X Volume X.; 2014. http://www.iarc.fr/en/publications/pdfs-online/epi/sp164/. Accessed November 21, 2018. 4. Secretaria de Estado da Saúde de São Paulo. FOSP - Fundação Oncocentro de São Paulo. http://www.fosp.saude.sp.gov.br/. Accessed October 30, 2018. 5. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259. doi:10.1016/S0140-6736(00)02799-9
Archived tumor samples from Formalin-Fixed Paraffin-Embedded (FFPE) blocks or slides.
Gustavo Werutsky, MD
Latin American Cooperative Oncology Group
218 participants (actual enrollment reported by the registry).
First Submitted
April 25, 2019
First Posted
May 8, 2019
Study Start
August 1, 2019
Actual (reported)Contact the study team to confirm eligibility.
Centro Paulista de Oncologia
São Paulo, São Paulo, Brazil
Sírio Libanês
São Paulo, São Paulo, Brazil
Primary Completion
August 31, 2021
Actual (reported)Study Completion
February 28, 2022
Actual (reported)Last Updated
February 12, 2026
Record last verified: 2022-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: